New expectations in the treatment of anemia in chronic kidney disease

Abstract

The new drugs developed for the treatment of anemia in chronic kidney disease patients, together with their mechanisms of action are reviewed. At present, many of them are already in advanced stages of clinical trials and is expected to be incorporated into the therapeutic arsenal in the coming years. The potential benefits and possible limitations are also described.

Keywords: Anemia; Chronic kidney disease; Enfermedad renal crónica; Hepcidin; Hepcidina; Inhibidores de prolil-hidroxilasa; Prolyl-hidroxilase inhibitors; Sotatercept.